A combination of the protease inhibitor BI 201335 (120 mg per day), the polymerase inhibitor BI 207127 (400 mg or 600 mg three times a day) and ribavirin (1,000–1,200 mg per day) for 4 weeks was safe and efficacious in 32 treatment-naive patients chronically infected with HCV genotype 1. In the group given 600 mg of BI 207127, the virological response was 100% by day 29, compared with 73% in those given 400 mg. The response to this combination was rapid and strong, and none of the patients experienced a severe adverse event.